Supplementary Figure S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Kaplan-meier estimate for A, DOT and B, PFS in patients with and without reversions enrolled on LoF in BRCA1/2, RAD51p, or PALB2 in HRD associated tumor types (breast, prostate, pancreatic, ovarian) C) On-treatment BRCA1 reversion detected (RECIST and ctDNA cTF in Fig. 3D)